+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach



Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach



Radiology and Oncology 48(3): 257-266



Glioblastoma multiforme (GBM) is a brain tumour with a very high patient mortality rate, with a median survival of 47 weeks. This might be improved by the identification of novel diagnostic, prognostic and predictive therapy-response biomarkers, preferentially through the monitoring of the patient blood. The aim of this study was to define the impact of GBM in terms of alterations of the plasma protein levels in these patients. We used a commercially available antibody array that includes 656 antibodies to analyse blood plasma samples from 17 healthy volunteers in comparison with 17 blood plasma samples from patients with GBM. We identified 11 plasma proteins that are statistically most strongly associated with the presence of GBM. These proteins belong to three functional signalling pathways: T-cell signalling and immune responses; cell adhesion and migration; and cell-cycle control and apoptosis. Thus, we can consider this identified set of proteins as potential diagnostic biomarker candidates for GBM. In addition, a set of 16 plasma proteins were significantly associated with the overall survival of these patients with GBM. Guanine nucleotide binding protein alpha (GNAO1) was associated with both GBM presence and survival of patients with GBM. Antibody array analysis represents a useful tool for the screening of plasma samples for potential cancer biomarker candidates in small-scale exploratory experiments; however, clinical validation of these candidates requires their further evaluation in a larger study on an independent cohort of patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 053669725

Download citation: RISBibTeXText

PMID: 25177240

DOI: 10.2478/raon-2014-0014


Related references

Fractionation of the human plasma proteome for monoclonal antibody proteomics-based biomarker discovery 2: antigen identification by dot-blot array screening. Electrophoresis 34(20-21): 3064-3071, 2014

Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. Journal of Proteomics 96(): 1-12, 2014

Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget 8(27): 44141-44158, 2017

Novel pancreatic beta cell-specific proteins: antibody-based proteomics for identification of new biomarker candidates. Journal of Proteomics 75(9): 2611-2620, 2012

Identification by a proteomic approach of a plasma protein as a possible biomarker of illicit dexamethasone treatment in veal calves. Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment 31(5): 833-838, 2015

Differential gel-based proteomic approach for cancer biomarker discovery using human plasma. Methods in Molecular Biology 854: 223-237, 2012

Identification of phosphorylated MYL12B as a potential plasma biomarker for septic acute kidney injury using a quantitative proteomic approach. International Journal of Clinical and Experimental Pathology 8(11): 14409-14416, 2016

Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research 6(7): 2833-2840, 2007

Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach. Plos One 10(11): E0141876-E0141876, 2016

Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS. Bmc Neurology 10(): 112-112, 2011

Identification of CALM as the potential serum biomarker for predicting the recurrence of nasopharyngeal carcinoma using a mass spectrometry-based comparative proteomic approach. International Journal of Molecular Medicine 40(4): 1152-1164, 2017

Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. Journal of Proteome Research 9(11): 5557-5567, 2011

A proteomic approach based on multiple parallel separation for the unambiguous identification of an antibody cognate antigen. Electrophoresis 31(20): 3428-3436, 2011

Identification of the Transmembrane Glucose Regulated Protein 78 as a Biomarker for the Brain Cancer Glioblastoma Multiforme by Gene Expression and Proteomic Studies. Journal of Membrane Science & Technology 4(1): -, 2014

Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry. Journal of Proteome Research 9(8): 3912-3922, 2010